Last Price$94.32.5%
Market Cap$120.9B
2.7%
Peers median - 4.1%
16.5%
Peers median - 14.8%
53.6%
Peers median - 29.9%
7.4%
Peers median - 14.4%
Competing with MDT
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$120.9B | 6.2 | $114.6 21.5% undervalued | 14.7% | $33.2B | $5,467.0M | 2.7% | 16.5% | 52.7% | 7.4% | 53.6% | |
$242.4B | 7.0 | $174.5 24.5% undervalued | 19.2% | $42.0B | $6,351.0M | 4.6% | 15.1% | 55.6% | 25.3% | 31.4% | |
$154.5B | 6.7 | $34.2 67.4% overvalued | 55.5% | $16.7B | $2,438.0M | 17.6% | 14.6% | 67.0% | 8.0% | 50.7% | |
$150.5B | 6.6 | $305.1 22.7% overvalued | 12.0% | $22.6B | $3,487.0M | 10.2% | 15.4% | 62.8% | 14.6% | 28.4% | |
$43.4B | 6.1 | $54.1 24.2% overvalued | (18.0%) | $5,872.6M | $502.2M | 0.9% | 8.6% | 77.8% | 25.8% | 7.4% | |
$34.9B | 7.0 | $43.1 49.8% overvalued | (29.7%) | $4,033.0M | $453.9M | 11.3% | 11.3% | 60.4% | 21.7% | 120.3% | |
$24.7B | 5.3 | $65.0 146.8% undervalued | 34.0% | €18.0B | €274.0M | (0.8%) | 1.5% | 43.1% | (4.2%) | 63.4% | |
$21.9B | 6.2 | $199.6 10.4% overvalued | (3.8%) | $5,398.4M | $751.4M | (0.2%) | 13.9% | 44.7% | 8.2% | 1.9% | |
$21.6B | 5.9 | $181.2 72.0% undervalued | (15.3%) | $5,655.4M | $1,132.4M | (23.5%) | 20.0% | 64.3% | 4.5% | 43.0% | |
$19.4B | 7.9 | $134.5 50.7% overvalued | 62.5% | $1,900.3M | $303.0M | 12.0% | 15.9% | 76.4% | 29.7% | 6.9% | |
$13.6B | 6.0 | $190.0 8.5% undervalued | (43.2%) | $3,999.0M | $622.7M | 3.5% | 15.6% | 70.3% | 14.2% | 2.3% |
Compare MDT Valuation Multiples with Peers
LTM
NTM
1Y Forward
2Y Forward
EV/Revenue
General
Valuation Multiple
Financial metrics
Company name
EV/Revenue
Revenue growth
EBITDA margin
Net Income margin
Medtronic plcMDT
4.4x
3.6%
(2.1%)
11.4%
Median Peer Set
6.4x
5.6%
126.3%
12.7%
Abbott LaboratoriesABT
5.9x
4.6%
134.5%
31.9%
Align Technology, Inc.ALGN
3.2x
3.4%
26.0%
11.5%
Boston Scientific CorporationBSX
9.9x
17.6%
16.7%
11.1%
DexCom, Inc.DXCM
8.6x
11.3%
(1.4%)
14.3%
Edwards Lifesciences CorporationEW
6.8x
(9.4%)
202.2%
76.7%
Koninklijke Philips N.V.PHG
1.6x
(0.8%)
118.1%
(3.9%)
Insulet CorporationPODD
9.7x
30.0%
4,364.6%
12.2%
STERIS plcSTE
4.1x
3.6%
257.9%
7.4%
Stryker CorporationSYK
7.0x
10.2%
(5.8%)
13.2%
Zimmer Biomet Holdings, Inc.ZBH
4.8x
6.5%
253.2%
13.8%
Compare MDT Valuation Multiples Dynamics with Peers
Crunching data... Almost there!
FAQ
1. How does Medtronic plc (MDT) revenue growth compare to peers and the industry?
Medtronic plc (MDT) revenue growth is 2.7%, compared to the peers' median of 4.1%.
2. How does Medtronic plc (MDT) Free Cash Flow (FCF) margin compare to peers and the industry?
Medtronic plc (MDT) FCF margin is 16.5%, compared to the peers' median of 14.8%.
3. How does Medtronic plc (MDT) Total Debt to Equity ratio compare to peers and the industry?
Medtronic plc (MDT) Total Debt to Equity ratio is 53.6%, compared to the peers' median of 29.9%.
4. How does Medtronic plc (MDT) ROIC (Return on Invested Capital) compare to peers and the industry?
Medtronic plc (MDT) ROIC is 7.4%, compared to the peers' median of 14.4%.